Otsuka Holdings Co., Ltd.

An unusual hybrid of prescription drugs and consumer beverages, pairing the antipsychotic Rexulti with Pocari Sweat and Bon Curry.

An Otsuka group facility

Business Description

Otsuka Holdings runs two very different businesses of comparable weight. Pharmaceuticals concentrates on central-nervous-system and oncology drugs, led by Rexulti for schizophrenia and depression, the digital therapeutic pipeline, and Jynarque for kidney disease; nutraceuticals covers the sports drink Pocari Sweat, the Calorie Mate nutrition bar, Bon Curry retort food and Nature Made supplements.

That pairing is deliberate: the consumer arm generates steady cash while the drug arm carries the patent cliffs, and the group has repeatedly funded pharmaceutical R&D through periods when a major product lost exclusivity. The holding company was created in 2008 to combine Otsuka Pharmaceutical with the food and beverage companies of the Otsuka group, whose origins go back to a chemical business founded in Tokushima in 1921. It reports on a December fiscal year.

Corporate Data

Ticker4578
ExchangeTokyo Stock Exchange
Size CategoryTOPIX Large70
Market SegmentPrime Market
SectorPharmaceuticals
Head OfficeShinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan
FoundedJuly 8, 2008
Fiscal Year EndDecember 31
WebsiteOfficial website

Latest Coverage

No articles have been published for this company yet.

JapanStockPulse provides informational content only and does not constitute investment advice. All figures are sourced from publicly available company disclosures and may be subject to revision.